| Biomarker ID | 1453 |
| PMID | 24938534 |
| Year | 2014 |
| Biomarker | Glutathione (GSH) |
| Biomarker Basis | Concentration Based (μmol/mL) |
| Biomolecule | Protein |
| Source | Blood |
| Subjects | Humans |
| Regulation | Downregulated after treatment with SeMet for 9 months (0.22 ± 0.07 change from baseline) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Baseline Vs 9 months later after treatment with SeMet |
| Type of Biomarker | Predictive |
| Cohort | A total of 130 subjects were randomized, of which 69 were included in the analysis. Out of 69 - 18 were allocated to Placebo, 16 were allocted to low dose SY (selenium-enriched yeast), 15 were allocated to high dose SY and 31 to SeMet (selenomethionine) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | NA |
| Clinical | Yes |
| Remarks | NA |
| Clinical Trial Number | NCT01112449 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |